Trial Profile
Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Ezetimibe (Primary)
- Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms PRECISE-IVUS
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
- 17 Apr 2013 Planned End Date changed from 1 Jan 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 02 Feb 2013 Primay endpoint amended as reported by University Hospital Medical Information Network - Japan record.